Use of antibiotic in contraceptive trial sparks controversy
BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7433.188-a (Published 22 January 2004) Cite this as: BMJ 2004;328:188- Ganapati Mudur
- New Delhi
A clinical trial in India's West Bengal state evaluating the antibiotic erythromycin as a female contraceptive has sparked controversy 15 months after the study ended, with doctors accused of pursuing illegal and unethical research.
A paper published this month in the international journal Contraception (2004;69:47-9) says that transcervical administration of erythromycin seemed very safe but had an “unacceptably high” failure rate of 28-35% per cent after 12 months. The volunteers were divide into two groups. Each woman in the first group received a 500mg tablet of erythromycin, while each woman in the second group received ten 50mg pellets of the drug. In both cases thetablets or pellets were placed in …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.